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2 stress disorder (PTSD), depression, and anxiety (Boyle, Vance, Najman, & Thearle, 1996) . A cohort study found that 29% of women met criteria for PTSD in pregnancy subsequent to stillbirth (Turton, Evans, & Hughes, 2009 ). Other studies have found an association between child death and anxiety, depression, psychiatric hospitalization, and completed suicide (e.g., Qin & Mortenson, 2011) .
Faced with a patient in acute bereavement and with awareness of the potential for long-term psychological sequelae, clinicians have several options for meaningful intervention. Psychosocial care on the part of clinicians clearly has an important role, ideally including patient-centered psychosocial care (Cacciatore, 2010) . Physicians can refer bereaved parents to support groups and/or to non-medical helping professionals for evidence-based psychotherapy (e.g., Shear, Frank, Houch, & Reynolds, 2005) . However, there is a paucity of well-replicated interventional research for traumatic bereavement, raising the question of whether any of the currently available psychosocial interventions can be said to be evidence-based.
Psychiatric medications are another potential intervention, and physicians sometimes prescribe sedatives such as benzodiazepines (BZs) for bereavement. A survey of obstetricians found that roughly half believed that BZs could be a useful to bereaved parents who recently lost an infant (Gold, Schwenk, & Johnson, 2008 ; see also Cook, Biyanova, & Marshall, 2007) . Only one randomized controlled trial (RCT) of BZs for acute bereavement has taken place (Warner, Metcalfe, & King, 2001 ). This small trial found no positive impact of BZs on either grief severity or sleep, and patients randomized ACCEPTED MANUSCRIPT ACCEPTED MANUSCRIPT 3 to diazepam reported more sleep problems. In a survey of the RCT participants, some opined that BZs could be helpful, but the majority also agreed that the prescription of BZ can "delay coming to terms with loss" (Warner et al., 2001, p. 40) . None of the participants developed BZ dependence, likely due to the close monitoring within the RCT. However, the potential for short-term BZ use to lead to dependence remains a concern within real-world clinical practice (van Hulter, Teeuw, Bakker, & Leufkens, 2003) . Data suggesting that BZs are not helpful in the recently traumatized should also be considered (Gelpin, Bonnie, Peri, Brandes, & Shalev, 1996) . Antidepressant (AD) medications are also an option for the treatment of bereavement. There are several studies for both bereavement-related depression and complicated grief. The limitations of the evidence for antidepressants have been noted (Bui, Nadal-Viens, & Simon, 2012) . The trials are small, not randomized, and/or demonstrate a statistically significant impact on symptoms of clinical depression, but no clinically important impact on grief severity or duration. Several open-label trials find a positive impact for ADs (Bui et al., 2012) . However, psychopharmacological trials are easily confounded by the placebo effect (Kirsch, 2010) and confirmatory bias; without double-blind, randomized controlled trials, it is not possible to isolate the clinical impact of ADs from the potential presence of rater bias or expectancy effects (e.g., Gaudiano & Herbert, 2005) and especially problematic to assert that ADs are superior to other forms of clinical intervention, such as evidence-based psychotherapy.
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In short, at present, there exists no rigorous evidence to support the prescription of ADs in bereavement. Yet, it is common for ADs to be prescribed off-label for conditions which do not have supporting RCT evidence (e.g., McManus, Mant, Mitchell, Britt, & Dudley, 2003) . Given the serenic-like effects of ADs (Glenmullen, 2000) , they are likely to be prescribed to the bereaved. The positive effects must be carefully balanced with other issues, such as the overestimation of AD efficacy (Kirsch, 2010; Turner, Matthews, Linaradatos, Tell, & Rosenthal, 2008) , the medicalization of grief (Moules, 1998) , and the risk of adverse effects, including discontinuation syndrome (Gentile, 2011; Haddad, 2001 ).
Distinct from the use of BZs, a prescription for an AD can be viewed as implicitly assuming that the patient is being treated for a long-term problem, and that short-term relief is not the goal. Selective serotonin reuptake inhibitors (SSRIs), the most-prescribed class of ADs, are generally not considered to provide a short-term benefit, often taking 14-30 days to take full effect (Nirenberg et a., 2009) . They are therefore inappropriate for short-term use. Treatment guidelines suggest that depressed patients complete ≥ 4-6 months of treatment (e.g., American Psychiatric Association, 2000). Patients are more likely to discontinue ADs early when the prescriber is a non-psychiatrist and/or the diagnosis is not depression or anxiety (Pomerantz et al., 2004) .
In terms of both evidence-based medicine and evidence-based psychosocial intervention, the interrelated issues of acute bereavement, psychiatric diagnosis (Yehuda, Mcfarlane, & Shalev, 1998) . Similarly, the diagnosis of complicated grief proposed for DSM-5 (Shear, et al., 2011) requires that the bereaved individual be at no less than six months post-loss and have experienced significant impairment for the last month.
Thus, the practice of prescribing ADs to bereaved individuals shortly after a loss is questionable. This is particularly true given that the intense clinical distress manifested immediately after a loss is often a poor predictor of long-term functioning (Neimeyer & Currie, 2009 ). Arguably, a conservative approach to prescribing, which would maximize benefit and minimize risk, would be to reserve ADs until it was clear that the patient met full criteria for MDD, PTSD, or, perhaps complicated grief as proposed for DSM-5. At present, though, there is a paucity of empirical data regarding psychiatric prescribing in response to perinatal/neonatal death, when diagnosis and prognosis are uncertain but patients are in significant clinical distress.
The objective of this study was to describe patterns of psychiatric medication prescribing among parents who had experienced the perinatal/neonatal death of a child. Specifically, we examined the: (1) rate at which psychiatric medications were prescribed to deal with loss, and the types of medication used; (2) time lapse between loss and prescription across different prescriber specialties; (3) demographic and clinical variables associated with the prescription of medication; and (4) persistence of treatment. answer the question on psychiatric medication, and, as we sought to assess prescription patterns in response to loss, we censored any cases taking psychiatric medication at the time of loss (n = 32), leaving 235 cases for analysis.
The majority of respondents were women (n = 227, 99.6%), had education beyond high school (n = 206, 87.7%), were Caucasian/White (n = 195, 82.3%) and had experienced an unexpected perinatal/neonatal death (n = 123, 52.3%), most frequently, a stillbirth (n = 168, 71.5%). Only a small proportion (n = 21, 8.7%) had been diagnosed with a mental disorder at the time of their loss. Of the 235 respondents, 88 (37.4%) had been prescribed psychiatric medication at some point in response to their loss.
Measures Demographic And Clinical Variables
Each respondent completed a demographic questionnaire (age, race/ethnicity, education) as well as questions regarding the circumstances of the death of their child. We asked whether the child death had been a stillbirth, whether the death was expected, and at what ACCEPTED MANUSCRIPT ACCEPTED MANUSCRIPT 8 point in the pregnancy/neonatal period it took place. We also asked "In the months before the loss, were you diagnosed with any mental health condition?", followed by a list of common mental health conditions. Respondents were also asked about their participation in professional counseling and support groups.
Self-Report Of Psychiatric Prescribing History
Respondents were asked, "Have you ever been prescribed psychiatric medications to deal with your loss?"; those who answered affirmatively were piped to a series of detailed questions, including a list of prescribed medications, the specialty of the clinician who initially prescribed them, and the time delay between loss and prescription. Respondents were then asked if they were still on medications and asked to list them; if they were no longer on medication, we asked the date of discontinuation.
We classified prescriptions into the following discreet categories: No psychiatric prescription in response to loss; BZ /sleep aid only; antidepressant monotherapy only; or combination treatment. Combination treatment referred to the combination of two ADs or an AD plus an additional medication. Trazadone was classified as a sleep aid in all cases except for one, in which other available data suggested that it was prescribed for depression.
Procedure
Pilot testing of survey questions among stakeholders helped refine the survey. 
RESULTS
Frequency And Type Of Medication
Of the 88 bereaved parents who received medication, 20.5% (n = 18) received a prescription for BZ or sleep aid monotherapy, 39.8% (n = 35) received AD monotherapy, and 39.8% (n = 35) received treatment with a combination of psychiatric drugs.
Combination treatment primarily consisted of AD + BZ and/or sleep aids (n = 23, 26.1%). Four participants (4.5%) received a medication combination including an antipsychotic; two had a mental health diagnosis in the months preceding the loss. The most popularly prescribed antidepressants were sertraline, fluoxetine, and escitalopram, while the most popular benzodiazepines were lorazepam and alprazolam, and zolpidem was the most frequently prescribed sleep aid.
Medications By Prescriber Specialty And Time-Since-Loss
Prescriptions were cross-tabulated by time-to-prescription and specialty of the prescriber (see table 1). Medication was frequently prescribed shortly after the loss; 32.2% (n = 28) were written within 48 hours, 43.7% (n = 38) within a week, and 74.7% (n = 65) within a month. Obstetricians/gynecologists wrote the majority of prescriptions written less than a month after loss (n = 46, 70.8%). Of the prescriptions written by OB/GYNs, 78.3% (n = 36) were for AD or combination therapy. Of those 36 bereaved parents receiving AD or combination treatment from their OB/GYN, nine reported that they were diagnosed with a mental disorder at the time of loss.
Demographic And Clinical Variables Associated With Prescribing
We performed a series of exploratory logistic regressions performed using one block and forced entry, examining variables that might increase the odds of receiving a prescription for ADs. The odds ratio for a mental health diagnosis at the time of loss was 3.66 (95% CI 1.04, 12.84, p = .043). All other variables examined (e.g., number of professional counseling sessions, support groups attended, stillbirth or not) did not reach statistical significance (Odds Ratios <1.04, p > .05 for all).
Persistence Of Treatment With Psychiatric Medication
Life table analysis was used to determine the median time-to-discontinuation for each category of medication (See figure 1) . For this analysis, we collapsed the categories of antidepressant monotherapy and combination treatment. As respondents sometimes reported moderate changes in medication regimen across time (e.g., changing from fluoxetine monotherapy to fluoxetine + zolpidem), this allowed us to quantify the persistence of treatment while retaining most data for analysis. Respondents who made more notable medication switches are discussed below. We included all respondents prescribed psychiatric medication < 6 months after loss for which we had usable data on stop and start dates (n = 75). We constrained the life table analysis to 730 days (two years).
For AD/combination treatment, discontinuation rates were similar for both those prescribed within a week of loss (median = 539 days) and those > 1 week < 1 month (median = 523 days). Approximately half of respondents in both groups had discontinued treatment within one year. The subsample of those prescribed AD/combination treatment > 1 month after loss (n = 12) discontinued treatment much earlier, at a median of 294 days, with only three such respondents (25%) continuing for the entire two-year period.
For those prescribed BZs or sleep aid monotherapy within four weeks of loss (n = 14), the median time to discontinuation was 60 days; from day 300 forward, only one respondent continued the original BZ prescription. 
Medication Status At Time Of Survey
Consistent with the life table analysis presented above, many respondents had discontinued their original medication, but some notable medication switches did occur (see table 2 ). The general trend otherwise was toward simplification of medication regimens; only 11 respondents were on multiple medications at the time of the survey (see table 2 ). All respondents originally placed on antipsychotics reported that they had been discontinued. Of the 18 respondents originally prescribed BZ/sleep aid therapy, 15 (83.3%) were off all medication; one remained on a benzodiazepine, and two had been switched to antidepressant monotherapy
DISCUSSION
In this cross-sectional survey of bereaved parents who suffered the perinatal/neonatal death of a child, we find that 37.4% (n =88) of the total sample (n = 235) have been prescribed medication to help deal with their loss. Most respondents who received medication were prescribed antidepressant (AD) medication (n = 70, 79.5% ) either as monotherapy or in combination with other medications. Most AD prescriptions were written < 4 weeks post-loss (n = 65, 73.9%), with OB/GYNs responsible for the largest proportion of AD prescriptions (n = 39, 44.8%). Many were written by OB/GYNs in the first week (n = 24, 27.6%), before these bereaved parents could have qualified for a diagnosis of PTSD or MDD, a questionable practice.
However, we begin by cautioning against a rush to judgment toward the prescribers within our sample. We do not have data on the patient-clinician interactions, and ACCEPTED MANUSCRIPT ACCEPTED MANUSCRIPT 13 bereaved parents may have requested medication. In general, contemporary mental health treatment is focused on use of medication (Kirk, Gomory & Cohen, 2013) . Both prescribers and patients in this sample have been subject to promotional efforts from pharmaceutical companies (i.e., Gomory, Wong, Cohen, & Lacasse, 2011) which may have shaped how they see mental distress and the role of psychiatric medication. Many prescribers undoubtedly do reach for the prescription pad too quickly, and the over-use of AD drugs in medicine is well-documented (e.g., Glenmullen, 2000) . However, the rate of prescription found in this study-29.8% receiving ADs in some form, and 7.7% receiving BZ or sleep aid monotherapy-should be seen in the context of contemporary psychiatric prescribing rates in other settings. In general practice, pseudopatients who reported depressive adjustment disorder symptoms were prescribed antidepressants 10% of the time when they did not directly request medication, and 39% of the time when they made a general request (Kravitz et al., 2005) . As respondents had contact with prescribers who are no doubt familiar with ADs, it seems only fair to note that 62.6% of this sample (on average, ~3 years post-loss) were never prescribed medication to deal with their loss.
Given the tragic nature of perinatal/neonatal death and the understandable inclination to do something to help, the prescribing practices observed here could be interpreted as reflecting therapeutic restraint.
That said, our primary finding is that many respondents received AD prescriptions shortly after loss from their OB/GYNs. OB/GYNs wrote such prescriptions for 15 patients (17.2%) within 48 hours of the death of a child, and for 24 patients (27.6%) within a week. There were only two other such prescriptions reported in the first week; one by a psychiatrist, the other by a primary care physician to a respondent previously diagnosed with multiple mental disorders. OB/GYNs thus prescribed 84.6% (n = 11) of all AD monotherapy and 100% (n = 13) of all combination therapy prescribed within seven days. One week of clinical symptoms is not sufficient for a DSM-IV-TR diagnosis of MDD or PTSD, and thus 60% (n = 24) of AD prescriptions written by OB/GYNs were for patients who could not have met diagnostic criteria for PTSD or MDD.
We know of no method through which a prescriber could reliably ascertain, so quickly, whether a recently bereaved parent would develop a sustained clinical problem best treated through ADs. Yehuda et al. (1998) examined clinical symptoms in response to trauma longitudinally. They found similar reactions for all patients at two days posttrauma, which separated a bit at day ten, with clear separation between no disorder, PTSD, depression and anxiety at six months. Such data suggests that prescribers simply cannot know the prognosis of acute bereavement. Indeed, awareness of such data may be one reason why the overall rate of prescribing was low. However, when ADs are prescribed shortly after loss, the purpose is essentially prophylaxis, which has been characterized as an overuse of AD medication (Conti, Bush and Cutler, 2011; Leo & Lacasse, 2010) . Assuming that ADs can only have positive effects in this context would seemingly be naïve, especially given emerging data on the complicated risk-benefit calculus regarding use of psychiatric medication (Whitaker, 2010) .
AD prescriptions often resulted in long-term treatment. Most strikingly, roughly half of those prescribed AD medication within a week of losing their child were still taking them two years later. Although BZs have a reputation for causing dependence, there is increasing recognition of an AD discontinuation syndrome that is of clinical concern (see Healy, 2004) . If avoiding long-term treatment with psychiatric medication is seen as preferable, the small subsample prescribed BZ/sleep aid therapy fared best. Almost all discontinued treatment rapidly and only one respondent took BZs long-term.
The use of SSRIs in women of childbearing age is also noteworthy, especially when prescribed without first exhausting psychosocial treatment options. SSRI use in pregnancy is associated with a long list of obstetrical problems, such as miscarriage, preterm birth and low birth weight (Urato, 2011, p. 190) . The odds ratio for congenital heart defects among women exposed to SSRIs in the first trimester of pregnancy is 2.01 (95% CI, 1.53, 2.72) which suggests that ADs should be used conservatively among fertile women (Jiminez-Solem et al., 2012) .
Our data are retrospective, observational data reached through a cross-sectional selfreport. We did not have access to clinical documentation, respondents could have made errors in their recollection of past events. There were no data collected on clinical interactions, and we did not ask bereaved parents if they requested medication. We surveyed participants in an on-line support community, a group that may differ from the larger population of bereaved parents. While the on-line support group was not oriented around the use of medication, selection bias remains a concern, and these findings should be replicated in other samples. Finally, these data were collected under the DSM-IV-TR, and the impending DSM-5 removes the bereavement exclusion (Thieleman & Cacciatore, 2013) . However, our results have a similar interpretation under DSM-5, which requires two weeks of symptoms to diagnosis MDD, and also cautions the clinician to consider context (bereavement) before diagnosing MDD.
Most respondents did not receive psychiatric medication, and among those that did, it seems likely that it was thought of as an early intervention strategy. While early intervention may have appeal to prescribers, the potential for unintended consequences should be considered. To draw a parallel from the psychological literature, immediate debriefing after trauma has been a frequently used intervention. The idea that immediate intervention could prevent PTSD seems commonsensical. However, careful analysis of intervention data showed that those receiving debriefing fared no better, and possibly worse, than those receiving no treatment at all. Some hypothesized that debriefing interferes with natural coping mechanisms (McNally, Bryant, & Ehlers, 2003) . Treatment guidelines now recommend against universal use of debriefing (Forbes et al., 2010) .
While the use of ADs in bereavement differs because of the lack of RCT data to settle the question, the debriefing example should give us pause. We do not know that AD treatment shortly after child death is helpful, and it could be harmful (Whitaker, 2010) .
CONCLUSION
A recent editorial in The Lancet stated, "Medicalising grief, so that treatment is legitimized routinely with antidepressants, for example, is not only dangerously simplistic, but also flawed. The evidence base for treating recently bereaved people with standard antidepressant regimens is absent" (p. 589). Thus, our findings should be disturbing. If intervention is needed in bereavement, there are many options beyond the use of psychopharmacology (e.g., Cacciatore & Flint, 2012) . Improving psychiatric practice in traumatic bereavement -especially among OB/GYNs who may reach for the prescription pad too quickly-has the potential to significantly improve care, and perhaps outcomes, for bereaved parents. We are concerned that current practices have the potential to cause harm, and hope the field can move toward a more evidence-based use of psychiatric medication.
#ACKNOWLEDGEMENT
We acknowledge the important contributions of Cynthia A. Lietz to the design and data collection phases of this study. We thank the many bereaved parents who took the time to participate in this study and share their experiences. 
